ArticleVirchows Archiv : an international journal of pathology2004
Expression of annexin II in conventional renal cell carcinoma is correlated with Fuhrman grade and clinical outcome.
Article in Virchows Archiv : an international journal of pathology, 2004. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 63 citations in OpenAlex.
- Effect of Annexin A2 on prognosis and sensitivity to immune checkpoint plus tyrosine kinase inhibition in metastatic renal cell carcinoma.Discover oncology · 2024Article
- Potential prognostic and therapeutic value of ANXA8 in renal cell carcinoma: based on the comprehensive analysis of annexins family.BMC cancer · 2023Article
- The intricate role of annexin A2 in kidney: a comprehensive review.Renal failure · 2023Review
- Annexin A2 and Kidney Diseases.Frontiers in cell and developmental biology · 2022Review
- Plasma membrane integrity in health and disease: significance and therapeutic potential.Cell discovery · 2021Review
- Annexin A2 in Inflammation and Host Defense.Cells · 2020Review
- Identification and Comparison of Differentiation-Related Proteins in Hepatocellular Carcinoma Tissues by Proteomics.Technology in cancer research & treatment · 2017Article
- Downregulation of a novel long non-coding RNA, LOC389332, is associated with poor prognosis and tumor progression in clear cell renal cell carcinoma.Experimental and therapeutic medicine · 2017Article
- Up-regulation of annexin A2 expression predicates advanced clinicopathological features and poor prognosis in hepatocellular carcinoma.Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2015Article
- Clinical significance of annexin II expression in human non-small cell lung cancer.Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2013Article
- Proteomics-based analysis of invasion-related proteins in malignant gliomas.Neuropathology : official journal of the Japanese Society of Neuropathology · 2013Article
- Three are better than one: plasminogen receptors as cancer theranostic targets.Experimental hematology & oncology · 2013Article
- Article
- Upregulated expression of annexin II is a prognostic marker for patients with gastric cancer.World journal of surgical oncology · 2012Article
- Kaposi's sarcoma-associated herpesvirus latency-associated nuclear antigen and angiogenin interact with common host proteins, including annexin A2, which is essential for survival of latently infected cells.Journal of virology · 2012Article
- The annexin A2/S100A10 system in health and disease: emerging paradigms.Journal of biomedicine & biotechnology · 2012Review
- The role of annexin A2 in tumorigenesis and cancer progression.Cancer microenvironment : official journal of the International Cancer Microenvironment Society · 2011Article
- The role of annexins I, II and IV in tumor development, progression and metastasis of human penile squamous cell carcinomas.World journal of urology · 2011Article
- Identification of cellular targets in human intrahepatic cholangiocarcinoma using laser microdissection and accurate mass and time tag proteomics.Molecular & cellular proteomics : MCP · 2010Article
- Annexin A2 is a molecular target for TM601, a peptide with tumor-targeting and anti-angiogenic effects.The Journal of biological chemistry · 2010Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Conventional renal cell carcinomas (CRCCs) were investigated for the expression of annexin II (ANX II) to determine out whether this calcium-binding protein could serve as a useful prognostic marker. CRCCs and adjacent nonneoplastic tissue from 33 patients were investigated for ANX II by immunohistochemistry, RT-PCR, and western blot analysis. ANX II expression was correlated with tumor differentiation (Fuhrman grade) and to clinical outcome. Tumors were composed of ANX II positive and negative cells. In grade I tumors only a weak membranous staining was seen in immunopositive cells. In grade II and III tumors, however, ANX II was seen in the cytoplasm and at the cell membranes of tumor cells. On serial sections membranous and cytoplasmic immunoreactivity for ANX II occurred predominantly in eosinophilic cells whereas clear cells were mostly immunonegative. The ANX II expression in CRCCs was correlated with clinical outcome and Fuhrman grade. Since ANX II expression is correlated with Fuhrman grade and clinical outcome it may be a useful marker for prognosis in CRCC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.